Research programme: natural killer T cell agonists - Revimmune SAS

Drug Profile

Research programme: natural killer T cell agonists - Revimmune SAS

Alternative Names: CYT 209

Latest Information Update: 12 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Aaron Diamond AIDS Research Center; City University of New York; New York University
  • Developer Revimmune SAS
  • Class Galactosylceramides
  • Mechanism of Action Natural killer cell stimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Immunological disorders; Infections

Most Recent Events

  • 13 Mar 2009 CYT 209 is still in preclinical trials for Cancer, Immunological disorders and Infections in France
  • 15 Feb 2008 Preclinical development is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top